Back to CVE records
Low 2.3Published Jul 6, 2026

CVE-2026-43928FOSSBilling is a free, open-source billing and client management system.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

FOSSBilling is a free, open-source billing and client management system. Prior to version 0.8.0, the PayPalEmail payment adapter accepts PayPal IPN callbacks and credits the IPN-supplied amount (`mc_gross`) to the client's balance without validating it against the invoice total. Combined with a $0.05 floating-point epsilon tolerance in the invoice credit-payment logic, this allows a client to underpay an invoice by up to $0.04 and still have it marked as fully paid. Version 0.8.0 patches the issue. There is no effective workaround without modifying the source code. Merchants using the PayPalEmail adapter should monitor IPN transactions for amounts that do not match their corresponding invoice totals, and manually review and refund suspicious payments.

CVSS
2.3 LOW (v4.0, NVD)CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Weakness (CWE)
CWE-754, CWE-1284
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Jul 7, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.